Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced it will present initial clinical data from Part A of its ongoing Phase 1/1b ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE